Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate
Benzinga Newsdesk 9 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over earnings of $0.12 per share
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $1.025 billion which missed the analyst consensus estimate of $1.026 billion by 0.11 percent. This is a 32.06 percent increase over sales of $776.133 million the same period last year.